Peer-influenced content. Sources you trust. No registration required. This is HCN.
Clinical Advances in Hematology & Oncology
The authors summarize the results of the major studies of ICB monotherapy and combinations; review novel combinations under investigation, including ICB with cellular therapies; and discuss potential candidate biomarkers for improving the selection of patients who may respond to ICB.
Obstetrics & Gynecology May 11th 2022
Journal of Clinical Oncology
The KRASG12C mutation was more prevalent in females and older patients and appeared to be associated with smoking status. KRASG12C tumors exhibited a distinct co-mutation profile and were associated with tumor mutational burden-high status.
Oncology, Medical May 4th 2022
A literature review involving 24 recent studies yielded an update to ASCO’s recommendations on appropriate use of breast cancer biomarker assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast cancer.
Medtelligence
The lipid metabolism plays an important role in the development of cardiovascular diseases and type 2 diabetes. However, little has been known about the molecular relationships. But now, a set of lipids have been statistically associated with cardiovascular disease and type 2 diabetes.
Cardiology May 3rd 2022
JAMA Network
In this case-control registry study of 63,828 patients with 14 common cancer types and 37,086 controls, pathogenic variants in BRCA1 were associated with biliary tract cancer, BRCA2 was associated with esophageal cancer, and combined BRCA1/2, with gastric cancer.
Oncology, Medical April 19th 2022
Predictive biomarkers are needed to identify patients with oropharyngeal squamous cell carcinoma (OPSCC) that could enjoy treatment de-escalation, with the attendant reduction in incidence of acute and late toxicities. In an observational study of consecutive patients with patients with oropharyngeal squamous cell carcinoma, pretreatment absolute lymphocyte count was predictive for 5-year overall survival. It also predicted benefit from the use of concurrent cisplatin chemotherapy.